We are live on
!
Find out more
SAM
Sectoral Asset Management Portfolio holdings
AUM
$121M
1-Year Est. Return
73.47%
This Fund
S&P 500
This Quarter
Est. Return
+14.67%
1 Year Est. Return
+73.47%
3 Year Est. Return
+165.77%
5 Year Est. Return
+169.27%
10 Year Est. Return
+1,136.49%
AUM
$2.63B
AUM Growth
+$404M
(+18%)
Cap. Flow
+$126M
Cap. Flow
% of AUM
4.79%
Top 10 Holdings %
Top 10 Hldgs %
47.42%
Holding
84
New
20
Increased
43
Reduced
13
Closed
7
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$64.6M |
| 2 |
Vertex Pharmaceuticals
VRTX
|
+$35.6M |
| 3 |
AGN
Allergan plc
AGN
|
+$33.5M |
| 4 |
ALDR
Alder Biopharmaceuticals
ALDR
|
+$26.6M |
| 5 |
Biogen
BIIB
|
+$23.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Regeneron Pharmaceuticals
REGN
|
+$76.2M |
| 2 |
NPSP
NPS PHARMACEUTICALS INC
NPSP
|
+$58.1M |
| 3 |
Amgen
AMGN
|
+$36.4M |
| 4 |
AGN
Allergan Inc
AGN
|
+$34.6M |
| 5 |
PTC Therapeutics
PTCT
|
+$23.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 90.54% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
GEVA
26
DELISTED
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
| $35.7M | 1.35% |
365,684
+1,800
| +0.5% | +$191K |
|
27
Medtronic
MDT
$111B
| $31.8M | 1.21% |
408,126
+98,101
| +32% | +$7.44M |
|
|
ACHN
28
DELISTED
Achillion Pharmaceuticals
ACHN
| $31.5M | 1.19% |
3,190,572
+816,762
| +34% | +$10.2M |
|
|
ALDR
29
DELISTED
Alder Biopharmaceuticals
ALDR
| $31M | 1.18% |
1,072,437
+968,137
| +928% | +$26.6M |
|
|
RLYP
30
DELISTED
RELYPSA INC COM
RLYP
| $30.2M | 1.15% |
837,830
+26,500
| +3% | +$956K |
|
31
United Therapeutics
UTHR
$26.1B
| $30.2M | 1.15% |
175,080
+12,200
| +7% | +$1.86M |
|
|
SGNT
32
DELISTED
SAGENT PHARMACEUTICALS INC COM STK (DE)
SGNT
| $27.2M | 1.03% |
1,170,083
+336,222
| +40% | +$8.9M |
|
|
MDVN
33
DELISTED
MEDIVATION, INC.
MDVN
| $27M | 1.02% |
417,778
-295,834
| -41% | -$16.9M |
|
34
DexCom
DXCM
$28.9B
| $24.9M | 0.95% |
1,598,232
+453,972
| +40% | +$6.86M |
|
|
MNTA
35
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
| $24.1M | 0.91% |
1,584,010
+124,407
| +9% | +$1.62M |
|
36
Align Technology
ALGN
$12.6B
| $23.3M | 0.88% |
433,140
+124,109
| +40% | +$7.07M |
|
|
XLRN
37
DELISTED
Acceleron Pharma
XLRN
| $22.8M | 0.87% |
599,184
-114,811
| -16% | -$4.57M |
|
38
Abbott
ABT
$187B
| $22.4M | 0.85% |
484,376
+78,966
| +19% | +$3.63M |
|
|
TTPH
39
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
| $22.2M | 0.84% |
+30,270
| New | +$22.7M |
|
|
AKRX
40
DELISTED
Akorn Inc
AKRX
| $22.2M | 0.84% |
466,668
+32,325
| +7% | +$1.47M |
|
41
Karyopharm Therapeutics
KPTI
$161M
| $21.6M | 0.82% |
47,151
+11,823
| +33% | +$5.1M |
|
|
CLVS
42
DELISTED
Clovis Oncology, Inc.
CLVS
| $18.5M | 0.7% |
249,152
-174,300
| -41% | -$12.3M |
|
43
Intuitive Surgical
ISRG
$130B
| $15.2M | 0.58% |
271,719
-38,025
| -12% | -$2.15M |
|
|
NXTM
44
DELISTED
NxStage Medical Inc.
NXTM
| $15.2M | 0.58% |
876,042
+69,030
| +9% | +$1.22M |
|
|
NVTA
45
DELISTED
Invitae Corporation
NVTA
| $14.7M | 0.56% |
+874,391
| New | +$16.2M |
|
|
HTWR
46
DELISTED
HEARTWARE INTERNATIONAL INC COM STK (DE)
HTWR
| $13.5M | 0.51% |
153,815
-14,710
| -9% | -$1.25M |
|
47
Ascendis Pharma A/S
ASND
$16.7B
| $12.7M | 0.48% |
+731,660
| New | +$13.3M |
|
48
HCA Healthcare
HCA
$92.8B
| $12.6M | 0.48% |
167,176
+23,174
| +16% | +$1.66M |
|
49
Novartis
NVS
$304B
| $11.8M | 0.45% |
133,256
+62,390
| +88% | +$5.53M |
|
50
Amphastar Pharmaceuticals
AMPH
$888M
| $11M | 0.42% |
733,932
+73,700
| +11% | +$985K |
|
Similar funds
RIP
LFWA
CF
WIM
MW
AFC
AAA
TGM
Sectoral Asset Management's Q1 2015 Portfolio in Review
As of Q1 2015, Sectoral Asset Management held 84 positions worth $2.63B, up 18% from $2.23B the previous quarter. Its ten largest holdings account for 47% of the portfolio.
Sectoral Asset Management deployed $126M of net new capital in Q1 2015, opening 20 new positions and adding to 43 existing holdings. Its largest new stake was Tetraphase Pharmaceuticals, Inc.: 30,270 shares worth $22.2M.
By sector, the portfolio is most concentrated in Healthcare at 91% of assets, up from 89% a quarter earlier.
On the sell side, the largest reduction was Amgen, an estimated $36.4M trimmed.
- Sectoral Asset Management's largest Q1 2015 buy was Tetraphase Pharmaceuticals, Inc.: 30,270 shares worth $22.2M.
- Sectoral Asset Management added most to Gilead Sciences in Q1 2015, an estimated $64.6M increase.
- Sectoral Asset Management's biggest Q1 2015 reduction was Amgen, cutting an estimated $36.4M.
- Sectoral Asset Management fully exited Regeneron Pharmaceuticals in Q1 2015, selling an estimated $76.2M.
- Sectoral Asset Management's ten largest holdings make up 47% of its $2.63B portfolio in Q1 2015.
- Sectoral Asset Management opened 20 new positions and closed 7 in Q1 2015.
- Sectoral Asset Management's portfolio value rose 18% quarter-over-quarter to $2.63B.
Based on Sectoral Asset Management's 13F filing for Q1 2015, filed 14 May 2015.